Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders (NCT05386134) | Clinical Trial Compass
RecruitingNot Applicable
Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders
Canada200 participantsStarted 2022-06-13
Plain-language summary
This is a Prospective Observational study. The aim of the study is to understand the underlying photoreceptor, retinal pigment epithelium or retinal vascular aberrations in inherited and acquired retinal disorders. The study would use adaptive optics (AO) technology to assist in-vivo visualization of these retinal structures and ascertain changes from normal. Further, by using the AO imaging in patients before and after treatments, this study aims to better understand the effect of various interventions and develop AO as an outcome measure in various retinal disorders.
Who can participate
Age range5 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Consent provided
✓. Aged 5 - 70 years
✓. Diagnosed with well documented retinal disorder
✓. Subjects aged 5 years - 70 years with normal eye examination.
✓. Patients with strabismus and otherwise normal visual acuity and eye examination
✓. Patients with unilateral eye diseases such as cataract, with a normal eye exam in the fellow eye.
Exclusion criteria
✕. Inability of the subject to maintain a stable position while seated
✕. Uncontrolled nystagmus, trembling or movements of the eyes or the head
✕. Presence of cataract or any opacity in the front of the eye that obscures retinal imaging
✕. Any general disease such neurological disease which could affect vision and the retina.
What they're measuring
1
To measure the change in Quantification of cone receptors
Timeframe: Primary outcome will be measured at Baseline, 6-months ,1 year. The patient data will be compared to the control data.
2
To measure the change in Quantification of the retinal pigment epithelium density
Timeframe: Primary outcomes will be measured at Baseline, 6-months ,1 year. The patient data will be compared to the control data.
3
To measure the change in Quantification of retinal blood vascular flow in retinal disorders
Timeframe: Primary outcomes will be measured at Baseline, 6-months ,1 year. The patient data will be compared to the control data.